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Despite the setbacks successes have been achieved.
Of the 18 SCID patients treated for their life threaten-
ing condition, 17 are still alive and have had a healthy,
functioning immune system for up to five years and a
good quality of life. In addition to monogenic
conditions, gene therapy also represents a viable treat-
ment for multigenic disorders, such as cancer, either as
a standalone treatment or in combination with chemo-
therapy or radiotherapy. A huge amount of work is yet
to be done, but with efficient monitoring of trials and
continuous improvements of viral vectors, gene
therapy may still represent an important addition to
the treatment armamentarium for a range of diseases.
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Lesson of the week
Mucocutaneous leishmaniasis: an imported infection among
travellers to central and South America
Sukhbir Ahluwalia, Stephen D Lawn, Jeevendra Kanagalingam, Henry Grant, Diana N J Lockwood
Leishmaniasis is caused by protozoan parasites
belonging to the genus Leishmania.1 2 The infection is
transmitted by phlebotomine sandflies, and a wide
range of domestic and wild vertebrates and humans
serve as reservoirs of infection. Leishmaniasis is
endemic throughout the Middle East, north Africa,
parts of Europe, and central and South America.1 2 The
worldwide prevalence is 12 million, with a tenth of the
world’s population at risk.
The infecting Leishmania species determines the
clinical presentation of disease, of which there are
three dominant clinical forms: cutaneous leishmania-
sis, mucocutaneous leishmaniasis (MCL), and visceral
leishmaniasis.1 2 Mucocutaneous disease is a chronic
inflammatory process involving the nasal, pharyngeal,
and laryngeal mucosa, which can lead to extensive tis-
sue destruction. MCL develops as a complication of
cutaneous leishmaniasis, parasites disseminating from
the primary cutaneous lesion via lymphatic vessels and
blood to reach the upper respiratory tract mucosa.
Such metastatic spread more commonly occurs with
species belonging to the L viannia subgenus (formerly
known as the L braziliensis complex), which are present
in tropical forested areas of central and South
America.1 2 MCL is estimated to develop as a complica-
tion of L viannia cutaneous leishmaniasis in 5-20% of
untreated patients living in areas where leishmaniasis
is endemic.3
Over the past 20 years, “exotic” foreign travel from
the United Kingdom has increased, resulting in more
cases of imported tropical infections. Increased aware-
ness of such diseases is important as early recognition
and treatment may improve outcome. Here we
describe three healthy British travellers who developed
MCL after travelling to Latin America. Each was man-
aged jointly at the Hospital for Tropical Diseases in
London by tropical medicine physicians and otorhi-
nolaryngologists. We emphasise the importance of a
history of travel to Latin America in patients
presenting with unusual skin lesions or chronic
nasopharyngeal symptoms and describe the diagnostic
process.
Fig 1 Patient with mucocutaneous leishmaniasis showing granulomatous lesion of septum (left); lesions on nasal alae (centre); nasal alae
after treatment (right)
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Case reports
Case 1
A month after a holiday in South America, a 38 year
old man was investigated at a regional centre for infec-
tious and tropical diseases for a persistent cutaneous
ulcer on his buttock and associated inguinal lympha-
denopathy. Biopsies failed to establish a diagnosis, and,
as the lesion was healing, the patient was discharged.
Nine months later, however, the patient developed
nasal congestion that persisted for six months until he
developed lesions on the exterior of his nose (fig 1,
left). Examination of the nasal mucosa showed a
granulomatous lesion of the septum (fig 1, centre), and
mucosal biopsies were obtained under topical anaes-
thesia. No parasites were found on microscopy or cul-
ture, but DNA of L viannia parasites was detected using
polymerase chain reaction, confirming a diagnosis of
MCL. He was treated with intravenous sodium
stibogluconate and made a full recovery (fig 1, right).
Case 2
A month after a school trip to Belize, a 17 year old
woman developed persistent erythema and swelling of
the nasal tip and rhinorrhoea. She was treated as an
inpatient at her local hospital with intravenous
antibiotics for suspected low grade bacterial cellulitis.
After referral to the Hospital for Tropical Diseases,
cutaneous and mucosal biopsies were negative on
microscopy and culture but polymerase chain reaction
was positive for L viannia DNA, establishing a diagno-
sis of MCL. She was successfully treated with sodium
stibogluconate.
Case 3
A 19 year old woman consulted her general
practitioner shortly after returning from extensive
travels in rural South America, complaining of persist-
ent skin ulcers and nasal congestion. Her doctor
contacted the Hospital for Tropical Diseases immedi-
ately concerned that her patient might have MCL. A
differential diagnosis of Wegener’s granulomatosis was
considered as the patient was known to have serum
antinuclear antibodies. Clinical examination showed
florid inflammation of the nasal and oropharyngeal
mucosa and five cutaneous ulcers with raised margins.
Diagnoses of cutaneous leishmaniasis and MCL
were established by positive culture and polymerase
chain reaction of mucosal and cutaneous biopsies.
She was successfully treated with intravenous sodium
stibogluconate.
Discussion
Mucocutaneous leishmaniasis is reported infrequently
among travellers returning from Latin America to
countries where the disease is not endemic.4–9 The
cases described here were all young healthy travellers
who had spent time in tropical forest areas of Latin
America; none had any risk factors for HIV infection.
MCL is endemic in such areas between southern
Mexico and the northern tip of Argentina.2 The trend
towards “adventure travel” to Latin America may lead
to MCL being more often imported to the United
Kingdom. Patients with MCL may present to a wide
variety of clinicians, including general practitioners, all
of whom should be aware of the potential significance
of a history of rural travel in Latin America. Familiarity
with the manifestations of cutaneous leishmaniasis
and MCL may speed diagnosis and limit disease
progression.
Recognition of cutaneous leishmaniasis lesions
may help to prevent development of MCL or facilitate
diagnosis of established MCL. The disease can be pre-
vented by treating L viannia cutaneous leishmaniasis
before mucosal involvement. Alternatively, in patients
with established mucosal disease, the presence of cuta-
neous leishmaniasis (or a history suggestive of a previ-
ous self healing cutaneous leishmaniasis lesion) may
provide a strong clue to a diagnosis of mucocutaneous
disease.
Cutaneous leishmaniasis lesions often develop on
exposed parts of the body within a few weeks of expo-
sure to infected sandfly bites. Single or multiple ulcers
typically have a raised, indurated margin and a sloughy
base (fig 2). There may be satellite lesions (sporotri-
choid spread) and cord-like infiltration of proximal
lymphatic vessels and local lymphadenopathy.
Fig 2 A 4 cm diameter cutaneous leishmaniasis ulcer on lower leg
caused by L viannia subgenus species showing the typical raised,
indurated margin
Box 1: Differential diagnosis for nasal
congestion
• Rhinitis (allergy)
• Anatomical cause (septal deviation, hypertrophic
turbinates)
• Hormonal disorder (puberty, pregnancy,
hypothyroidism, acromegaly)
• Granulomatous disease (sarcoidosis, Wegener’s
granulomatosis)
• Drug induced cause (rhinitis medicamentosa,
prazosin, cocaine)
• Impaction (crusts, foreign body)
• Mass (adenoids, nasal polyps, nasopharyngeal
carcinoma)
• Infection (leishmaniasis, tuberculosis, leprosy,
syphilis, rhinoscleroma, coccidioidomycosis,
histoplasmosis, blastomycosis)
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The differential diagnosis for cutaneous leishmania-
sis includes secondary infected insect bites, sporotricho-
sis (a fungal infection implanted into the skin by a thorn
or other penetrating injury), or more rarely cutaneous
tuberculosis. Appropriate drug treatment promotes
rapid healing of cutaneous leishmaniasis lesions, but the
great majority will heal spontaneously over several
months; such healing, however, does not preclude the
later development of MCL, as illustrated by case 1.
The most common symptom of MCL is persistent
nasal congestion, for which the differential diagnosis is
broad (box 1). Anterior nasal septal granulomas may
be visible with a light source and Thudicum’s
speculum, whereas posteriorly located granulomas
require nasendoscopy to be seen. Progressive MCL
lesions destroy upper respiratory tract mucosa over
months and years. Common sites are the turbinates
and nasal septum,7 9 where erosion of underlying tissue
and cartilage may result in perforation. Progressive tis-
sue destruction at the nasal mucocutaneous junction in
advanced disease may cause marked disfigurement,
requiring reconstructive surgery. Lesions may also
affect the palate, pharynx, and larynx, causing palatal
dysfunction, dysphagia, dysphonia, and aspiration.1 2
Bony structures are not involved.
Diagnoses of cutaneous leishmaniasis and MCL are
established by demonstrating the presence of Leishma-
nia parasites in infected tissues. Serology is rarely helpful
except in advanced MCL. Punch biopsies should be
taken from the raised, indurated edge of cutaneous
leishmaniasis lesions and sent fresh for microbiological
and parasitological examination and in formalin for his-
topathological assessment. Examination of Giemsa
stained impression smears for the presence of the intra-
cellular form of the parasites (amastigotes) may quickly
yield a diagnosis in some patients. Amastigotes may also
be seen in histopathological sections. The flagellate form
of the parasite (promastigote) may be cultured from
biopsies on modified Novy-McNeal-Nicolle medium
incubated for up to three weeks.
Polymerase chain reaction is the most sensitive
diagnostic test, however, and is also used to
differentiate L viannia subgenus infections, which are
associated with the greatest risk of MCL.10 11 Similarly,
in patients with suspected MCL, biopsies of mucosal
lesions are required for diagnosis, and additional biop-
sies may be taken from the turbinates even if these are
not overtly involved. Histopathology of mucosal biop-
sies shows granulomatous changes for which the
differential diagnosis is broad (box 2). Compared with
cutaneous leishmaniasis, Leishmania parasites are less
readily visualised or cultured from MCL lesions
because the vigorous host response limits the tissue
parasite burden. In recent years, however, polymerase
chain reaction has proved to be a sensitive tool.11
MCL requires prolonged parenteral treatment with
pentavalent antimonials (treatment of choice) or
amphotericin preparations. Such treatment is associ-
ated with toxicity and risk of relapse.1 2 Patients require
joint management from infectious or tropical diseases
physicians plus otorhinolaryngologists who have clini-
cal experience of MCL and access to the necessary
specialist laboratory investigations. Expeditious and
appropriate care, however, can be given only after the
diagnosis has been suspected.
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Box 2: Differential diagnosis for nasal
granulomas
• Bacterial infection (tuberculosis, leprosy, syphilis,
rhinoscleroma)
• Fungal infection (coccidioidomycosis,
histoplasmosis, blastomycosis, rhinosporidiosis)
• Parasitic infection (leishmaniasis)
• Autoimmune (Wegener’s granulomatosis, systemic
lupus erythematosis)
• Sarcoidosis
• Lymphoma
• Foreign body
• Heavy metals (beryllium, nickel)
• Idiopathic cause
Interactive case report
A 35 year old woman with diabetic nephropathy who wants a baby
This case was described on 18 and 25 September (BMJ 2004;329:
674, 729). Debate on the management of the patient continues on
bmj.com (http://bmj.com/cgi/eletters/329/7468/729). On 16
October we will publish the outcome of the case together with
commentaries on the issues raised by the management and
online discussion from the patient and relevant experts.
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